April 24th 2024
During a Case-Based Roundtable® event, Misako Nagasaka, MD, discussed treatment for a patient with non–small cell lung cancer and an EGFR exon 20 insertion.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
DNA in Urine Shows Promise as a Liquid Biopsy for Cancers and Rare Diseases
June 18th 2014Urinary cell-free DNA analysis had near-100% accuracy for detecting BRAF mutations associated with histiocytic disease, according to a small clinical study reported at the 2014 ASCO Annual Meeting in Chicago.
Read More
Tumor Mutational Analysis Using Urinary Cell-Free DNA
June 17th 2014Mutational analysis is emerging as a powerful tool in oncology; from the identification and validation of a tumor-specific genetic lesion, to the development of therapeutic agents, to the subsequent, longitudinal assessment of acquired mutations.
Read More
An Analysis of a Phase II study MK-2206 plus Erlotinib in NSCLC
June 12th 2014Karen L. Reckamp, MD, co-director, Lung Cancer and Thoracic Oncology Program, associate professor, City of Hope, the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.
Watch
Adding Necitumumab to Standard of Care Improves Survival in Squamous NSCLC
June 11th 2014Adding necitumumab to standard of care with gemcitabine-cisplatin improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) of squamous histology.
Read More
ARAF as a New Driver in Lung Adenocarcinoma
June 9th 2014Luiz H. Araujo, MD, medical oncologist, Corporate Cancer Foundation fellow, Ohio State’s Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute, discusses the discovery of oncogenic ARAF as a new driver for lung cancer.
Watch
Promise Seen With EGFR Inhibitor CO-1686 in Treatment-Resistant NSCLC
June 2nd 2014The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Read More
FDA Grants Breakthrough Therapy Designation for CO-1686 for EGFR T790M-Positive NSCLC
May 21st 2014The EGFR inhibitor CO-1686 has received a breakthrough therapy designation from the FDA for its potential as a treatment for patients with metastatic T790M mutation-positive non-small cell lung cancer (NSCLC) who have received at least one prior line of EGFR-targeted therapy.
Read More
Immune Checkpoint Inhibitors in NSCLC
May 7th 2014Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, discusses the variety of immune checkpoint inhibitors that are currently being explored as treatments for patients with non-small cell lung cancer (NSCLC).
Watch
MAGE-A3 Immunotherapeutic Fails to Improve DFS in NSCLC
April 3rd 2014The large phase III MAGRIT study investigating the MAGE-A3-specific vaccine GSK1572932A for patients with non-small cell lung cancer (NSCLC) will be completely halted following an interim analysis that demonstrated a lack of benefit.
Read More